Source: Siyu MedTech; Editor:Liu XinyiReprint Requirements: Please indicate the source of the article at the beginning of the text, and it can be reprinted directly.
On November 2, 2023, BD (NYSE: BDX) announced the launch of its FDA-approved needle-free blood collection technology.
# Born for "One-Stop Hospitalization"
PIVO™Upgraded Needle-Free Blood Collection DeviceFDA 510(k) approval has been obtained.The launch of this device helps to further realize BD's "One-Stick Hospitalization" plan, which was proposed two years ago, improving the patient experience.
PIVO™ Pro Needle-free Blood Collection DeviceAfter its design was improved,Currently the only one on the marketProducts compatible with integrated peripheral venous long catheters.can also collaborate with other subsidiaries under BDNexiva™Anti-Needle Stick Disposable Venous Catheter and NearPort™Used in conjunction with infusion adapters. The compatibility of the new version of the PIVO blood collection device and traditional peripheral venous short catheters since 2017 has greatly improved.
Nexiva™ Closed IV Catheter System and NearPort™ IV Access
BD stated that the new versionPIVO Device CombinesClosed Nexiva™ Catheter SystemThe clinical application advantages not only extend the device's usage time but also reduce potential adverse reactions caused by catheters. Additionally, the updated device can directly draw high-quality blood samples through the patient's peripheral venous catheter, thereby reducing the number of needle sticks. Studies have shown that over 60% of adults are afraid of needles, and this device helps alleviate patients' fear and anxiety associated with repeated needle sticks.Eric Borin, Global Head of BD's Medication Delivery Solutions, stated:"This timePIVO™The upgrade of the series of needle-free blood collection devices helps more patients and clinicians accept needle-free blood collection.At the same time, we will adhere to the concept of "one-needle hospitalization" to improve and revise medical standards... This device can reduce unnecessary repeated needle insertions in hospitals, enhance clinical outcomes, optimize hospital workflows, and provide a better experience for clinicians and patients.The PIVO™ series was launched in 2017 and has been continuously upgraded since then.This device brings patients a better healthcare experience by minimizing the number of needle sticks.To date, the United States has used more than 3.5 million units ofPIVO™ Device.Peripheral intravenous injection and blood collection are the two most common procedures in hospital inpatient departments, which patients undergo almost every day. Performing these invasive nursing procedures may lead to various issues, such as failed needle insertion, frequent problems with infusion catheters, prolonged hospital stays and increased costs due to poor sample quality, and a negative hospital experience for patients.As a global leader in drug infusion solutions, BD is committed to raising the standards of intravenous infusion and blood collection. The emergence of new technologies brings three major benefits: ① As long as the indwelling needle is correctly placed initially, the device can reduce the number of needle sticks; ② With just one intravenous line, both infusion and blood drawing can be achieved; ③ The intravenous line is easy to maintain, helping to reduce complications, and patients can use it for an extended period without needing replacement during their entire hospital stay.
BD Medical (NYSE:BDX) was founded in 1897,Headquartered inBecton, Dickinson and Company, New Jersey, USAProduction and sales include medical consumables, laboratory instruments, antibodies, reagents, diagnostics, and other products.In 2022, BD's global revenue was $18.869 billion (approximately $137.8 billion). BD ranked in 2023 on the Medical Design & Outsourcing website.GlobalRanked in the top 20 on the list of the top 100 medical device companies.In the first half of fiscal 2023, BD's total revenue was94.07billion US dollars (approximately 657 billion US dollars)）, a year-on-year decrease of 0.6%.
The three major businesses of BD Medical are the Medical Department, Life SciencesLearning and Intervention departments. In the first half of fiscal year 2023, these three businesses accounted for 48%, 27%, and 25% of total revenue respectively. Among them, the medical department increased by 5.6% year-on-year; the life sciences sector was significantly affected by the sharp decline in demand for COVID-19 testing.A decrease of 13.2% year-over-year; All sectors under the intervention department, including surgical operations, peripheral interventions, urology, and intensive care, maintained growth.An increase of 4.0% year-over-year。
Overseas Cardiovascular Devices:
Artivion | Abbott | Shockwave Medical | HVR Cardio | Abiomed |CardiacSense | Lydus Medical | Volta Medical |Cardiac Dimensions | HeartBeam | MedtronicRadiant | MedtronicAcQCross | Acutus Medical | Boston Scientific | Cardiovascular Systems | CVRx | Biotronik | Edwards Lifesciences |Cordis
Products of Chinese Cardiovascular Companies:
Huamai Tech | Heartpulse Medical | Bai Xin An | Venus Medtech | Lepu Medical | Lifetech Scientific | Minimally Invasive Medical | Becton, Dickinson and Company |
Editor-in-Chief | Zhao Qing Reviewed by | Yi He Typeset by | Miya
